Download Meridian Cancer Care Breast Clinical Trials

Meridian Cancer Care
Breast Clinical Trials
Novartis MONALEESA-7-A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in
combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the
treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast
cancer
Novartis MONALEESA-3- A randomized double-blind, placebo-controlled study of ribociclib in combination with
fulvestrant for the treatment of postmenopausal women with hormone receptor positive, HER-2 negative,
advanced breast cancer who have received no or only one line of prior endocrine treatment
ECOG 2112- A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with
Hormone Receptor-Positive Advanced Breast Cancer
ECOG 4112- is a prospective study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression
Assay in Ductal Carcinoma In Situ (DCIS)
A011202- A Randomized Phase III trial comparing axillary lymph node dissection to axillary radiation in breast
cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant
chemotherapy
RTOG 1304- A randomized phase III clinical trial evaluating post-mastectomy chestwall and regional nodal XRT
and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant
chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy
PUMA-NER 6201-An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with
Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis
CINJ 040406-4862 – Effect of DNA Variations on Breast Cancer Risk and Recurrence
CINJ 130404- Women’s Circle of Health Study (Breast Cancer Study in African American Women)
RCINJ-001209 PRECISION- Targeted genomic analysis of human cancer